Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Gemcitabine-induced Thrombotic Microangiopathies
NCT05702996Phase 3Withdrawn
- Sponsor
- Rouen University Hospital
- Start
- Mar 2023
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of eculizumab in thrombotic microangiopathy (TMA), sponsored by Rouen University Hospital. Planned start Mar 2023; status: withdrawn.
02
Drugs
eculizumab
03
Conditions
thrombotic microangiopathy (TMA)
Beyond the preview
Go deeper on NCT05702996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05702996.